Announcement • Jul 01
Eisai Co Ltd Showcases Alzheimer’s Disease Portfolio With Over 50 Presentations At Alzheimer’s Association International Conference 2026
Eisai Co Ltd. announced the company would present the latest findings from its Alzheimer’s disease (AD) research, including lecanemab (brand name: LEQEMBI), its anti-amyloid beta (Aß) protofibril antibody for the treatment of Alzheimer’s disease (AD), and anti-MTBR (microtubule binding region) tau antibody, etalanetug (E2814), at the Alzheimer’s Association International Conference 2026 (AAIC) from July 12-15 in London and online. Eisai will present 52 abstracts across its AD portfolio at AAIC. Highlights include a Developing Topics Session and a Featured Research Session on lecanemab, featuring four and six oral presentations, respectively, alongside 10 additional key oral presentations and 32 posters. Eisai will also host a symposium on early intervention in AD. A Developing Topics Session will feature emerging clinical evidence and practical use considerations for the subcutaneous formulation of lecanemab, including clinical trial and real-world patient experience. Presentations on the Phase 3 AHEAD 3-45 study in preclinical AD will highlight progress of the trial including updates on participant retention and engagement. Additional oral presentations will highlight a Phase 2 trial of etalanetug with background lecanemab, and the effect on tau pathology. Eisai will present findings on the subcutaneous formulation of lecanemab in early Alzheimer’s disease, including safety profile, clinical outcomes, and patient experience from an Alzheimer’s disease treatment center, as well as real-world patient-reported outcomes with subcutaneous lecanemab treatment in early Alzheimer’s disease in the United States. The LEADER study will provide a three-year update of lecanemab in early Alzheimer’s disease, including use and clinical outcomes by APOE e4 status, concomitant medications, sex, race, and ethnicity, real-world use of lecanemab once-monthly maintenance dosing, the first reported findings of at-home subcutaneous lecanemab administration, real-world insights on lecanemab maintenance therapy patient pathway, and physician and perceived patient satisfaction with lecanemab maintenance therapy. Additional presentations will cover treatment actions following ARIA in patients treated with lecanemab, sex-based outcomes of lecanemab in early Alzheimer’s disease, external controls in open-label extensions, broad modulation of core tau biomarkers including pTau205 following lecanemab treatment, tau PET change in CLARITY-AD, racial and ethnic differences in %p-tau217 associations with cognitive performance and amyloid PET in preclinical AD, lecanemab clinical practice from the ALZ-NET Registry, baseline imaging characteristics of participants in a Phase 2 trial of etalanetug and concurrent lecanemab, etalanetug and tau tangle specific plasma eMTBR-tau243 in DIAD, refining plasma pTau217/Aß42 cutoffs for amyloid positivity in an Asian cohort with high cerebrovascular disease burden, and more. Poster presentations will include characterization and utilization assessment of a centrally supported ride-share service implemented in a multisite preclinical Alzheimer’s clinical trial, long-term persistence and patient characteristics for intravenous and subcutaneous lecanemab in real-world use in the United States, retrospective case series of real-world clinical and patient-reported outcomes with lecanemab, retrospective observational cohort study of real-world clinical and patient-reported outcomes with lecanemab, subcutaneous lecanemab administration in an Alzheimer’s disease treatment center, INITIATE-SC multicenter real-world study of subcutaneous lecanemab initiation in early Alzheimer’s disease, continued or time-limited treatment benefits of anti-amyloid monoclonal antibodies in early Alzheimer’s disease, real-world analysis from a Colorado neurological clinic, communicating participant milestones to enhance trial engagement and retention in a preclinical Alzheimer’s trial, initial real-world experience in using lecanemab in Hong Kong, real-world lecanemab treatment in early Alzheimer’s disease from a geriatric medicine clinical practice, time and motion and patient satisfaction study of subcutaneous injection of lecanemab, differential costs of amyloid-related imaging abnormality management between anti-amyloid treatments, VISION AD-JP prospective multicenter real-world study of Japanese patients with early Alzheimer’s disease treated with lecanemab, real-world outcomes with lecanemab treatment in a New England Alzheimer’s disease center, estimating the economic impact of delayed Alzheimer’s disease progression with lecanemab, economic, health, and quality-of-life burden on caregivers and study partners of lecanemab-treated individuals with Alzheimer’s disease, surrogate antibody of etalanetug and uptake of tau monomer and aggregate in human macrophages, novel CSF eMTBR-tau243 immunoassay for detecting AD tau pathology and assessing etalanetug pharmacodynamics in DIAD, blood-based biomarkers in early Alzheimer’s disease, confirmatory blood-based biomarkers and diagnostic timing in Alzheimer’s disease, practical factors influencing the use of confirmatory blood-based biomarkers in Alzheimer’s care, frontline perspectives on the real-world use of blood-based biomarkers in Alzheimer’s disease, evolution of real-world blood-based biomarker use in the lecanemab patient pathway, retrospective analysis of costs of amyloid diagnostic tests for Alzheimer’s disease, piloting digital cognitive assessments and a blood-based biomarker to improve Alzheimer’s disease diagnosis, real-world diagnostic pathways for Alzheimer’s disease in U.S. clinical practice, integrated peptide-level global proteomics and co-expression network analysis, proteomic assessment of CSF biomarkers of neurodegeneration from a minimally invasive and serial CSF collection technique in mice, driving time to infusion sites as an obstacle to receiving Alzheimer’s treatments, treatment goals for anti-amyloid therapy in early-AD, and interpreting evidence for self-administered digital cognitive assessments. South Korea, Taiwan, and Saudi Arabia, and is under regulatory review in 6 countries. Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority. Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.